Lucid Diagnostics, a subsidiary of PAVmed, has developed a quick, office-based test called EsoCheck to detect esophageal precancer in patients with heartburn or acid reflux. This test aims to address the lack of early detection programs for esophageal cancer, which is often diagnosed late with poor outcomes. EsoCheck, a noninvasive device, collects cells from the esophagus to analyze genetic markers associated with precancer and cancer. The convenience of EsoCheck could potentially increase screening rates for the 30 million at-risk patients each year. Lucid is hopeful for approval from Medicare and commercial insurers for coverage of their product.
Source link
This Pill-Size Diagnostic Seeks to Prevent Thousands of Esophageal Cancer Deaths
